Compare PRPO & BHM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRPO | BHM |
|---|---|---|
| Founded | N/A | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Real Estate Investment Trusts |
| Sector | Industrials | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.0M | 35.5M |
| IPO Year | 2000 | 2022 |
| Metric | PRPO | BHM |
|---|---|---|
| Price | $23.21 | $8.20 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 84.8K | 2.0K |
| Earning Date | 11-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.24% |
| EPS Growth | ★ 92.15 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $24,049,000.00 | ★ $68,734,000.00 |
| Revenue This Year | $233.72 | $1.31 |
| Revenue Next Year | $22.61 | $11.18 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 29.77 | ★ 36.88 |
| 52 Week Low | $16.40 | $7.87 |
| 52 Week High | $33.63 | $13.30 |
| Indicator | PRPO | BHM |
|---|---|---|
| Relative Strength Index (RSI) | 40.20 | 41.86 |
| Support Level | $22.09 | N/A |
| Resistance Level | $24.95 | $8.97 |
| Average True Range (ATR) | 1.18 | 0.27 |
| MACD | -0.11 | -0.00 |
| Stochastic Oscillator | 18.10 | 2.50 |
Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. Its objective is to enhance diagnostic accuracy & accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, & Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division & the Products Division. The Pathology Services provides specialized cancer diagnostic testing services. The pathology services division specializes in diagnostic testing focused mainly on hematologic cancers.
Bluerock Homes Trust Inc owns and operates a portfolio of institutional residential properties including single-family homes, build-to-rent communities, and other residential communities located in attractive markets with a focus on the knowledge-economy and high-quality of life growth markets of the Sunbelt and Western United States. The company's principal objective is to generate attractive risk-adjusted returns on investments where it believes it can drive growth in funds from operations and net asset value by acquiring residential units, developing residential communities, and through value-add renovations. The company has two reportable segments, consisting of Residential Communities, which derives maximum revenue; and Scattered Single-family homes.